Emerging angiogenesis inhibitors for non-small cell lung cancer
Authors:
- 3 April 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 24 (2) , 71-81
Abstract
Introduction: Angiogenesis represent a complex process crucial during embryo development, wound healing, and collateral formation for improved organ perfusion. Numerous stimulatory and inhibitory pathways through their balance regulate angiogenesis and vascular homeostasis. Targeting the pathways implicated in the regulation of angiogenesis and neo-angiogenesis play an important role in cancers research, treatment and patients’ outcome. Antiangiogenic strategies, including monoclonal antibodies binding vascular endothelial growth factor (VEGF) or the corresponding receptor and small molecules which inhibit the function of different angio–related tyrosine kinase, produced interesting results in cancer treatments including non-small-cell lung cancer (NSCLC). Areas covered: The current state-of-the-art of anti-angiogenesis treatment in the management of NSCLC patients is reviewed and discussed. A structured search of bibliographic databases for peer-reviewed research literature and of main meetings using a focused review question was undertaken in order to discuss about emerging angiogenesis inhibitors in NSCLC. Expert opinion: Targeting angiogenesis remains an important therapeutic strategy in the management of NSCLC. Moreover, VEGF has been recognized having also an immunosuppressive activity leading to investigate the potential activity of angiogenic inhibitors in restoring the antitumor immunity by targeting VEGF/VEGF-Receptor. Furthermore, new anti-angiogenic drugs for which there is also the availability of predictive biomarkers are welcome.Keywords
This publication has 59 references indexed in Scilit:
- Axitinib for the treatment of advanced non-small-cell lung cancerExpert Opinion on Investigational Drugs, 2013
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Annals of Oncology, 2010
- Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNFJournal of Oncology, 2010
- Targeting Tumor AngiogenesisSeminars in Oncology, 2009
- Lenalidomide: a novel anticancer drug with multiple modalitiesExpert Opinion on Pharmacotherapy, 2008
- The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaProceedings of the National Academy of Sciences, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survivalThe FASEB Journal, 2001
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971